Skip to content
Screener

Recursion Pharmaceuticals, Inc. RXRX Total Liabilities & Equity

Total Liabilities & Equity at other companies

Schrodinger logo
SchrodingerSDGR
$640.39M-7.0%
Absci Corporation logo
Absci CorporationABSI
$195.59M-15.9%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$1.31B-6.7%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$967.46M+32.7%
Septerna, Inc. logo
Septerna, Inc.SEPN
$566.74M+36.5%
Xencor logo
XencorXNCR
$724.96M-17.6%

Other financials

Income statement

See full
Revenue$7.7M-60.1%
Gross profit-$3.8M-307%
Operating income-$135.0M+23.4%
Net income-$131.0M+23.8%
EPS (diluted)-$0.25+39.0%

Balance sheet

See full
Cash & equivalents$556.8M+4.3%
Total debt$80.5M-27.2%
Total equity$915.0M-0.5%
Total assets$1.2B-6.9%

Cash flow

See full
Operating cash flow-$105.9M-38.6%
CapEx$44.0K-98.6%
Free cash flow-$106.0M-33.2%

Valuation

See full
Market cap$1.7B-28.6%
Enterprise value$1.22B-37.5%
P/S31×-5.9×

Profitability

See full
Gross margin3.5%
Operating margin-991.7%-13.7pp
Net margin-945.9%-52.4pp
FCF margin-642.2%+36.1pp

Returns & leverage

See full
Return on equity-56.6%-14.5pp
Debt / equity0.1×0.0×
Current ratio+1.5×

Where this comes from

Reported directly by Recursion Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 6:32 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001601830-26-000098
Line itemJune 30, 2026December 31, 2025
Commitments and contingencies (Note 7)
Stockholders’ equity
Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of June 30, 2026 and December 31, 2025; 534,120,235 shares (Class A 533,191,318, Class B — and Exchangeable 928,917) and 528,182,693 shares (Class A 521,831,046, Class B 5,547,334 and Exchangeable 804,313) issued and outstanding as of June 30, 2026 and December 31, 2025, respectively55
Additional paid-in capital3,211,5153,170,145
Accumulated deficit(2,324,511)(2,076,002)
Accumulated other comprehensive income27,99436,717
Total stockholders’ equity915,0031,130,865
Total liabilities and stockholders’ equity$1,212,668$1,474,130

Item 1. Financial Statements (unaudited)

FAQ

What is Recursion Pharmaceuticals, Inc.'s total liabilities & equity?
Recursion Pharmaceuticals, Inc. (RXRX) reported total liabilities & equity of $1.21B in Q2 2026.
How has Recursion Pharmaceuticals, Inc.'s total liabilities & equity changed year-over-year?
Recursion Pharmaceuticals, Inc.'s total liabilities & equity decreased by 6.9% year-over-year, from $1.3B to $1.21B.
What is the long-term trend for Recursion Pharmaceuticals, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s total liabilities & equity has grown at a 37.6% compound annual growth rate (CAGR), from $298.59M to $1.47B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Recursion Pharmaceuticals, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude